GoodRx Holdings, Inc. (NASDAQ:GDRX) Insider Buys $537,047.64 in Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) insider Scott Wagner bought 104,079 shares of GoodRx stock in a transaction dated Thursday, November 16th. The shares were bought at an average price of $5.16 per share, for a total transaction of $537,047.64. Following the completion of the transaction, the insider now directly owns 104,079 shares of the company’s stock, valued at approximately $537,047.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

GoodRx Stock Up 0.6 %

Shares of GDRX stock opened at $5.23 on Monday. The firm has a fifty day moving average of $5.39 and a 200-day moving average of $5.91. The company has a quick ratio of 8.23, a current ratio of 8.23 and a debt-to-equity ratio of 0.74. GoodRx Holdings, Inc. has a 12-month low of $4.14 and a 12-month high of $9.37. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of 130.75, a P/E/G ratio of 5.41 and a beta of 1.17.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Thursday, November 9th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. GoodRx had a net margin of 2.04% and a return on equity of 2.25%. The company had revenue of $180.00 million during the quarter, compared to the consensus estimate of $188.52 million. During the same quarter in the prior year, the firm earned $0.07 earnings per share. The firm’s revenue was down 3.9% compared to the same quarter last year. As a group, equities research analysts predict that GoodRx Holdings, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

GDRX has been the subject of a number of recent research reports. Credit Suisse Group boosted their price target on shares of GoodRx from $7.00 to $8.00 and gave the stock a “neutral” rating in a research note on Thursday, August 10th. Royal Bank of Canada dropped their price target on shares of GoodRx from $8.00 to $5.00 and set a “sector perform” rating for the company in a research note on Friday, November 10th. JPMorgan Chase & Co. dropped their price target on shares of GoodRx from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Friday. Truist Financial dropped their price target on shares of GoodRx from $8.00 to $5.50 and set a “hold” rating for the company in a research note on Friday, November 10th. Finally, DA Davidson raised shares of GoodRx from a “neutral” rating to a “buy” rating and set a $9.50 price target for the company in a research note on Thursday, August 10th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $7.97.

Institutional Investors Weigh In On GoodRx

Several large investors have recently made changes to their positions in the stock. Moneta Group Investment Advisors LLC increased its position in shares of GoodRx by 112,694.0% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 17,148,069 shares of the company’s stock worth $79,910,000 after acquiring an additional 17,132,866 shares in the last quarter. Vanguard Group Inc. boosted its holdings in GoodRx by 10.4% during the third quarter. Vanguard Group Inc. now owns 7,830,341 shares of the company’s stock worth $36,568,000 after purchasing an additional 739,017 shares during the last quarter. Millennium Management LLC boosted its holdings in GoodRx by 151.3% during the fourth quarter. Millennium Management LLC now owns 5,318,603 shares of the company’s stock worth $24,785,000 after purchasing an additional 3,202,061 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in GoodRx by 459.0% in the third quarter. Ameriprise Financial Inc. now owns 2,631,227 shares of the company’s stock valued at $14,814,000 after acquiring an additional 2,160,541 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in GoodRx by 11.2% in the second quarter. Renaissance Technologies LLC now owns 2,498,122 shares of the company’s stock valued at $13,790,000 after acquiring an additional 250,800 shares during the last quarter. Institutional investors own 33.63% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.